GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IRIDEX Corp (NAS:IRIX) » Definitions » Asset Turnover

IRIX (IRIDEX) Asset Turnover : 0.43 (As of Dec. 2024)


View and export this data going back to 1996. Start your Free Trial

What is IRIDEX Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. IRIDEX's Revenue for the three months ended in Dec. 2024 was $12.70 Mil. IRIDEX's Total Assets for the quarter that ended in Dec. 2024 was $29.64 Mil. Therefore, IRIDEX's Asset Turnover for the quarter that ended in Dec. 2024 was 0.43.

Asset Turnover is linked to ROE % through Du Pont Formula. IRIDEX's annualized ROE % for the quarter that ended in Dec. 2024 was -141.36%. It is also linked to ROA % through Du Pont Formula. IRIDEX's annualized ROA % for the quarter that ended in Dec. 2024 was -11.25%.


IRIDEX Asset Turnover Historical Data

The historical data trend for IRIDEX's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRIDEX Asset Turnover Chart

IRIDEX Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.16 1.41 1.25 1.35 1.53

IRIDEX Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.36 0.34 0.39 0.38 0.43

Competitive Comparison of IRIDEX's Asset Turnover

For the Medical Devices subindustry, IRIDEX's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IRIDEX's Asset Turnover Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, IRIDEX's Asset Turnover distribution charts can be found below:

* The bar in red indicates where IRIDEX's Asset Turnover falls into.


;
;

IRIDEX Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

IRIDEX's Asset Turnover for the fiscal year that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=48.669/( (34.436+29.135)/ 2 )
=48.669/31.7855
=1.53

IRIDEX's Asset Turnover for the quarter that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=12.696/( (30.154+29.135)/ 2 )
=12.696/29.6445
=0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


IRIDEX  (NAS:IRIX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

IRIDEX's annulized ROE % for the quarter that ended in Dec. 2024 is

ROE %**(Q: Dec. 2024 )
=Net Income/Total Stockholders Equity
=-3.336/2.36
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-3.336 / 50.784)*(50.784 / 29.6445)*(29.6445/ 2.36)
=Net Margin %*Asset Turnover*Equity Multiplier
=-6.57 %*1.7131*12.5612
=ROA %*Equity Multiplier
=-11.25 %*12.5612
=-141.36 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

IRIDEX's annulized ROA % for the quarter that ended in Dec. 2024 is

ROA %(Q: Dec. 2024 )
=Net Income/Total Assets
=-3.336/29.6445
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-3.336 / 50.784)*(50.784 / 29.6445)
=Net Margin %*Asset Turnover
=-6.57 %*1.7131
=-11.25 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


IRIDEX Asset Turnover Related Terms

Thank you for viewing the detailed overview of IRIDEX's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


IRIDEX Business Description

Traded in Other Exchanges
N/A
Address
1212 Terra Bella Avenue, Mountain View, CA, USA, 94043
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
Executives
Nandini Devi director 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Beverly A Huss director C/O ACCURAY INCORPORATED, 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Robert Earle Grove director 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Topcon Corp 10 percent owner 75-1, HASUNUMA-CHO, ITABASHI-KU, TOKYO M0 174-8580
Topcon America Corp 10 percent owner 111 BAUER DRIVE, OAKLAND NJ 07426
Fuad Ahmad officer: Interim CFO 461 SOUTH MILPITAS BLVD., MILPITAS CA 95035
Doris Engibous director C/O NATUS MEDICAL INCORPORATED, 1501 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Scott Shuda director 402 RAILROAD AVENUE, SUITE 201, DANVILLE CA 94526
Patrick Mercer officer: COO 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Maria Sainz director C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Ruediger Naumann-etienne director
Robert A Gunst director
David Bruce director, officer: President and CEO 1178 GLEN ROAD, LAFAYETTE CA 94549
Ken Ludlum director
Romeo R Dizon other: Vice President and Controller 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043